BioMark Diagnostics Inc
CNSX:BUX
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
B
|
BioMark Diagnostics Inc
CNSX:BUX
|
51.5m CAD |
Loading...
|
|
| US |
|
Natera Inc
NASDAQ:NTRA
|
28.4B USD |
Loading...
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
19.4B USD |
Loading...
|
|
| FR |
|
Biomerieux SA
PAR:BIM
|
11.5B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
13.1B USD |
Loading...
|
|
| US |
C
|
Caris Life Sciences Inc
NASDAQ:CAI
|
7.2B USD |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.2B CNY |
Loading...
|
|
| CH |
|
Siegfried Holding AG
SIX:SFZN
|
4.2B CHF |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.4T KRW |
Loading...
|
|
| IT |
|
DiaSorin SpA
MIL:DIA
|
4B EUR |
Loading...
|
|
| UK |
|
Abcam PLC
LSE:ABC
|
2.8B GBP |
Loading...
|
Market Distribution
| Min | -9 940 586.9% |
| 30th Percentile | -85.9% |
| Median | -7.8% |
| 70th Percentile | 5.5% |
| Max | 60 777.6% |
Other Profitability Ratios
BioMark Diagnostics Inc
Glance View
BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-11-03. The Company’s cancer diagnostic solutions can help detect, monitor and assess treatment for cancer. Its cancer diagnostics technology platform leverages Omics and machine learning, which allows for early cancer detection. The firm is focused on bringing its cancer diagnostic kits and detection solution to commercialization standards. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The firm has developed a liquid biopsy metabolic panel assay. This metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for BioMark Diagnostics Inc is -1 110.4%, which is below its 3-year median of -1 098.7%.
Over the last 3 years, BioMark Diagnostics Inc’s Net Margin has increased from -1 985.3% to -1 110.4%. During this period, it reached a low of -1 985.3% on May 30, 2022 and a high of -874.6% on Mar 31, 2024.
